Abstract
Recently, we demonstrated that radiolabelled interleukin-lα (IL-1) specifically accumulates in focal infection in mice through interaction with its receptor. Unfortunately, systemic side-effects of IL-1 limit its clinical application. We investigated whether this problem could be circumvented by using the interleukin-1 receptor antagonist (IL-Ira), an equally sized protein that binds to the same receptors as IL-1 without induction of biological effects. Biodistribution of125I-IL-1 and125I-IL-Ira was determined in Swiss mice withStaphylococcus aureus-induced abscesses in the left calf muscle at 4, 12, 24 and 48 h after injection of either 0.4 MBq125I-IL1 or 0.4 MBq125I-IL-Ira. In vitro, the proteins displayed similar binding characteristics. High-performance liquid chromatographic analysis revealed a tendency for IL-Ira to associate with serum proteins. Both proteins rapidly cleared from most organs. However, the abscess uptake of125I-IL-Ira was significantly lower than that of125I-IL-1 at all time points (48 h p.i.: 0.06±0.01%ID/g vs 0.60±0.04%ID/g;P<0.02). The abscess-to-contralateral muscle ratios did not exceed 15.5±2.9 for125I-IL-lra, while the ratios for125I-IL-1 reached 46.9±5.7 at 48 h p.i. Despite similar in vitro receptor binding, the abscess uptake of IL-Ira was much lower than that of IL-1. The interaction of IL-Ira with serum proteins in vivo may reduce its availability for receptor binding in the infection. Although on theoretical grounds IL-Ira is very interesting, these characteristics will prevent its development as a clinically useful radiopharmaceutical to image infection.
References
Peters AM, Danure HJ, Osman S, et al. Preliminary clinical experience with Tc-99m-HMPAO for labelling leucocytes and imaging infection.Lancet 1986; II: 945–949.
Oyen WJG, Claessens RAMJ, Raemakers JMM, de Pauw BE, van der Meer JWM, Corstens FHM. Diagnosing infection in febrile granulocytopenic patients with indium-111 labelled human IgG.J Clin Oncol 1992; 10: 61–68.
Van der Laken CJ, Boerman OC, Oyen WJG, et al. Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model.Eur J Nucl Med 1995; 22: 1249–1255.
Smith J, Urba W, Steis R, et al. Interleukin-1 alpha: results of a phase I toxicity and immunomodulatory trial.Am Soc Clin Oncol 1990; 9:717.
Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-I (IL-1) receptor antagonist binds to the 80 kD IL-1 receptor but does not initiate signal transduction.J Biol Chem 1991; 266: 10331–10336.
Granowitz EV, Porat R, Mier JW et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans.Cytokine 1992;4:353–360.
Wilbur DS, Hadley SW, Hylarides MD, et al. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer.J Nucl Med 1989; 30: 216–226.
Zubler RH, Erard F, Lees RK, et al. Mutant EL-4 thymoma cells polyclonally activate murine and human B cells via direct cell interaction.J Immunol. 1985: 134: 3662.
Dinarello CA. Interleukin-1 and interleukin-1 antagonism.Blood 1991; 77: 1627–1652.
Matsushime H, Roussel MF, Matsushima K, Hishinuma A, Sherr CJ. Cloning and expression of murine interleukin-1 receptor antagonist in macrophages stimulated by colony-stimulating factor 1.Blood 1991; 78: 616–623.
Curtis BM, Widmer MB, deRoos P, Qwarnstrom EE. IL-1 and its receptor are translocated to the nucleus.J Immunol 1990; 144:1295–1303.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van der Laken, C.J., Boerman, O.C., Oyen, W.J.G. et al. Different behaviour of radioiodinated human recombinant interleukin-1 and its receptor antagonist in an animal model of infection. Eur J Nucl Med 23, 1531–1535 (1996). https://doi.org/10.1007/BF01254480
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01254480